CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Verrica Pharmaceuticals Inc. - VRCA CFD

3.86
2.12%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Verrica Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.78
Open* 3.64
1-Year Change* 20.93%
Day's Range* 3.64 - 3.87
52 wk Range 2.02-8.70
Average Volume (10 days) 217.68K
Average Volume (3 months) 8.86M
Market Cap 175.83M
P/E Ratio -100.00K
Shares Outstanding 42.06M
Revenue 8.61M
EPS -0.53
Dividend (Yield %) N/A
Beta 2.02
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 3.86 0.23 6.34% 3.63 3.88 3.63
Sep 28, 2023 3.78 0.10 2.72% 3.68 3.83 3.64
Sep 27, 2023 3.78 -0.01 -0.26% 3.79 3.91 3.71
Sep 26, 2023 3.91 0.12 3.17% 3.79 4.09 3.79
Sep 25, 2023 3.89 0.20 5.42% 3.69 3.90 3.67
Sep 22, 2023 3.75 0.00 0.00% 3.75 3.84 3.70
Sep 21, 2023 3.72 -0.12 -3.12% 3.84 3.88 3.66
Sep 20, 2023 3.97 0.13 3.39% 3.84 4.12 3.84
Sep 19, 2023 4.00 0.15 3.90% 3.85 4.02 3.83
Sep 18, 2023 3.90 -0.09 -2.26% 3.99 4.03 3.85
Sep 15, 2023 4.01 -0.06 -1.47% 4.07 4.13 3.96
Sep 14, 2023 4.17 0.08 1.96% 4.09 4.25 4.01
Sep 13, 2023 4.12 -0.14 -3.29% 4.26 4.41 4.04
Sep 12, 2023 4.27 0.13 3.14% 4.14 4.30 4.01
Sep 11, 2023 4.17 0.09 2.21% 4.08 4.25 4.01
Sep 8, 2023 4.25 0.08 1.92% 4.17 4.33 4.06
Sep 7, 2023 4.16 -0.06 -1.42% 4.22 4.22 4.08
Sep 6, 2023 4.20 -0.13 -3.00% 4.33 4.42 4.18
Sep 5, 2023 4.33 -0.11 -2.48% 4.44 4.56 4.32
Sep 1, 2023 4.60 0.14 3.14% 4.46 4.76 4.34

Verrica Pharmaceuticals Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Verrica Pharmaceuticals Inc Earnings Release
Q3 2023 Verrica Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Monday, February 19, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Verrica Pharmaceuticals Inc Earnings Release
Q4 2023 Verrica Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 9.032 12 0 0 0
Revenue 9.032 12 0 0
Total Operating Expense 31.765 42.908 40.181 30.08 21.878
Selling/General/Admin. Expenses, Total 17.405 26.979 24.508 14.644 9.052
Research & Development 12.198 15.929 15.673 15.436 12.826
Operating Income -22.733 -30.908 -40.181 -30.08 -21.878
Interest Income (Expense), Net Non-Operating -1.696 -4.172 -2.512 1.877 1.231
Net Income Before Taxes -24.487 -35.08 -42.694 -28.207 -20.648
Net Income After Taxes -24.487 -35.08 -42.694 -28.207 -20.648
Net Income Before Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
Net Income -24.487 -35.08 -42.694 -28.207 -20.648
Income Available to Common Excl. Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
Income Available to Common Incl. Extra. Items -24.487 -35.08 -42.694 -28.207 -20.648
Diluted Net Income -24.487 -35.08 -42.694 -28.207 -20.648
Diluted Weighted Average Shares 34.1634 27.0445 24.9956 24.8979 25.8099
Diluted EPS Excluding Extraordinary Items -0.71676 -1.29712 -1.70806 -1.13291 -0.8
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.6747 -1.29712 -1.70806 -1.13291 -0.8
Other, Net -0.058 -0.001 -0.004 -0.001
Total Adjustments to Net Income 0
Cost of Revenue, Total 0.725
Gross Profit 8.307
Unusual Expense (Income) 1.437
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.182 0.037 0.068 8.319 0.214
Revenue 0.182 0.037 0.068 8.319 0.214
Total Operating Expense 11.798 7.126 6.279 8.308 9.335
Selling/General/Admin. Expenses, Total 5.937 4.319 3.189 3.925 5.173
Research & Development 5.725 2.739 2.365 2.946 4.162
Operating Income -11.616 -7.089 -6.211 0.011 -9.121
Interest Income (Expense), Net Non-Operating 0.626 0.5 0.286 0.067 -1.046
Net Income Before Taxes -10.99 -6.589 -5.932 0.083 -10.168
Net Income After Taxes -10.99 -6.589 -5.932 0.083 -10.168
Net Income Before Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
Net Income -10.99 -6.589 -5.932 0.083 -10.168
Income Available to Common Excl. Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
Income Available to Common Incl. Extra. Items -10.99 -6.589 -5.932 0.083 -10.168
Diluted Net Income -10.99 -6.589 -5.932 0.083 -10.168
Diluted Weighted Average Shares 45.9169 43.0234 41.1702 44.6562 27.5191
Diluted EPS Excluding Extraordinary Items -0.23935 -0.15315 -0.14408 0.00186 -0.36949
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.23935 -0.15315 -0.14408 0.03404 -0.36949
Other, Net 0 -0.007 0.005 -0.001
Unusual Expense (Income) 0 1.437
Cost of Revenue, Total 0.136 0.068 0.725
Gross Profit 0.046 -0.031 -0.657
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 39.115 74.328 67.65 64.983 91.152
Cash and Short Term Investments 34.273 70.354 65.47 62.017 89.809
Cash & Equivalents 34.273 15.752 10.686 9.241 10.271
Prepaid Expenses 4.355 3.974 2.18 2.966 1.343
Total Assets 44.721 80.125 74.154 68.424 91.906
Total Current Liabilities 3.459 46.055 39.475 3.351 2.477
Accounts Payable 0.507 0.845 0.348 1.185 0.922
Payable/Accrued 0.038
Accrued Expenses 2.952 3.511 3.312 2.166 1.517
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 4.688 47.52 41.168 3.409 2.477
Total Long Term Debt 0 0.016 0 0 0
Total Equity 40.033 32.605 32.986 65.015 89.429
Redeemable Preferred Stock 0
Common Stock 0.004 0.003 0.003 0.003 0.003
Additional Paid-In Capital 203.482 171.597 136.868 126.594 122.526
Retained Earnings (Accumulated Deficit) -163.453 -138.966 -103.886 -61.192 -33.083
Total Liabilities & Shareholders’ Equity 44.721 80.125 74.154 68.424 91.906
Total Common Shares Outstanding 41.0941 27.5191 25.4411 25.807 25.7048
Property/Plant/Equipment, Total - Net 5.33 5.502 4.938 2.201 0.255
Other Long Term Assets, Total 0.276 0.295 1.566 1.24 0.499
Treasury Stock - Common 0 0 0 0
Short Term Investments 0 54.602 54.784 52.776 79.538
Property/Plant/Equipment, Total - Gross 6.029 5.756 5.065 2.285 0.275
Accumulated Depreciation, Total -0.699 -0.254 -0.127 -0.084 -0.02
Other Equity, Total -0.029 0.001 -0.39 -0.017
Other Liabilities, Total 1.229 1.449 1.693 0.058
Current Port. of LT Debt/Capital Leases 0 41.699 35.315
Other Current Liabilities, Total 0 0.5
Capital Lease Obligations 0 0.016
Total Receivables, Net 0.487
Long Term Debt 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 63.097 39.115 43.395 57.341 65.772
Cash and Short Term Investments 59.952 34.273 39.454 14.398 21.904
Cash & Equivalents 59.952 34.273 32.473 5.43 10.407
Short Term Investments 0 6.981 8.968 11.497
Total Receivables, Net 0.056 0.487 0.419 0.218 0.431
Prepaid Expenses 3.089 4.355 3.522 2.725 3.437
Total Assets 68.639 44.721 49.147 63.436 71.617
Property/Plant/Equipment, Total - Net 5.173 5.33 5.531 5.626 5.703
Property/Plant/Equipment, Total - Gross 6.003 6.029 6.1 6.076 6.055
Accumulated Depreciation, Total -0.83 -0.699 -0.569 -0.45 -0.352
Other Long Term Assets, Total 0.369 0.276 0.221 0.469 0.142
Total Current Liabilities 2.643 3.459 3.078 45.711 44.8
Accounts Payable 0.575 0.507 0.137 0.714 0.531
Accrued Expenses 2.068 2.952 2.941 2.697 2.264
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 42.3 42.005
Other Current Liabilities, Total
Total Liabilities 3.793 4.688 4.382 47.103 46.199
Total Long Term Debt 0 0 0 0.013 0.015
Other Liabilities, Total 1.15 1.229 1.304 1.379 1.384
Total Equity 64.846 40.033 44.765 16.333 25.418
Common Stock 0.004 0.004 0.004 0.003 0.003
Additional Paid-In Capital 234.884 203.482 202.311 173.998 172.913
Retained Earnings (Accumulated Deficit) -170.042 -163.453 -157.521 -157.604 -147.436
Treasury Stock - Common 0 0 0 0
Other Equity, Total -0.029 -0.064 -0.062
Total Liabilities & Shareholders’ Equity 68.639 44.721 49.147 63.436 71.617
Total Common Shares Outstanding 41.8521 41.0941 41.0941 27.5191 27.5191
Capital Lease Obligations 0 0 0.013 0.015
Other Current Assets, Total 40 40
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -24.487 -35.08 -42.694 -28.207 -20.648
Cash From Operating Activities -18.65 -27.582 -30.207 -27.408 -17.874
Non-Cash Items 7.183 7.789 10.809 2.463 1.816
Cash Interest Paid 1.789 2.85 1.875 0 0
Changes in Working Capital -1.8 -0.535 1.635 -1.728 0.938
Cash From Financing Activities -16.87 33.646 35.232 0.423 99.376
Financing Cash Flow Items -0.017 0 0.319 0 -7.881
Issuance (Retirement) of Stock, Net 26.901 28.676 0.453 0.423 107.257
Net Change in Cash 18.521 5.066 1.445 -1.03 1.608
Cash From Operating Activities 0.454 0.244 0.043 0.064 0.02
Cash From Investing Activities 54.041 -0.998 -3.58 25.955 -79.894
Capital Expenditures -0.302 -0.883 -1.47 -0.682 -0.275
Other Investing Cash Flow Items, Total 54.343 -0.115 -2.11 26.637 -79.619
Issuance (Retirement) of Debt, Net -43.754 4.97 34.46
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -6.589 -24.487 -18.555 -18.638 -8.47
Cash From Operating Activities -4.59 -18.65 -13.696 -15.521 -8.34
Cash From Operating Activities 0.131 0.454 0.323 0.196 0.098
Non-Cash Items 1.165 7.183 5.92 3.228 1.725
Cash Interest Paid 0 1.789 1.788 1.468 0.725
Changes in Working Capital 0.703 -1.8 -1.384 -0.307 -1.693
Cash From Investing Activities -0.011 54.041 47.287 45.218 43.013
Capital Expenditures -0.011 -0.302 -0.236 -0.159 -0.005
Other Investing Cash Flow Items, Total 0 54.343 47.523 45.377 43.018
Cash From Financing Activities 30.28 -16.87 -16.87 -0.019 -0.018
Issuance (Retirement) of Stock, Net 30.308 26.901 26.901 0 0
Issuance (Retirement) of Debt, Net 0 -43.754 -43.754 -0.002 -0.001
Net Change in Cash 25.679 18.521 16.721 29.678 34.655
Financing Cash Flow Items -0.028 -0.017 -0.017 -0.017 -0.017

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Verrica Pharmaceuticals Inc. Company profile

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing novel treatments for skin diseases. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through single-use precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a contagious and primarily pediatric viral skin disease, and common warts. It is conducting Phase II clinical trial for the treatment of plantar warts.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Verrica Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 18% to $35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-Based Compensation in SG&A decrease of 50% to $4.5M (expense), Research and development - Balancing val decrease of 3% to $14.4M (expense).

Industry: Pharmaceuticals (NEC)

10 N High St Ste 200
WEST CHESTER
PENNSYLVANIA 19380-3014
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

XRP/USD

0.53 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

ETH/USD

1,729.34 Price
+3.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

US100

14,834.40 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Oil - Crude

90.19 Price
+0.180% 1D Chg, %
Long position overnight fee 0.0661%
Short position overnight fee -0.0881%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading